anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
Participants will receive 3 preoperative 21-day cycles of Durvalumab + Tremelimumab + Enfortumab Vedotin, followed by radical cystectomy, followed by 1 cycle of postoperative Tremelimumab and 9 cycles of Durvalumab. Each postoperative cycle is 28 days.
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.
The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
An ingestible pill platform for colon imaging is provided, designed to recognize its entry to the colon and expand in the colon, for improved imaging of the colon walls. On approaching the external anal sphincter muscle, the ingestible pill may contract or deform, for elimination. Colon recognition may be based on a structural image, based on the differences in diameters between the small intestine and the colon, and particularly, based on the semilunar fold structure, which is unique to the colon. Additionally or alternatively, colon recognition may be based on a functional image, based on the generally inflammatory state of the vermiform appendix. Additionally or alternatively, pH, flora, enzymes and (or) chemical analyses may be used to recognize the colon. The imaging of the colon walls may be functional, by nuclear-radiation imaging of radionuclide-labeled antibodies, or by optical-fluorescence-spectroscopy imaging of fluorescence-labeled antibodies. Additionally or alternatively, it may be structural, for example, by visual, ultrasound or MRI means. Due to the proximity to the colon walls, the imaging in accordance with the present invention is advantageous to colonoscopy or virtual colonoscopy, as it is designed to distinguish malignant from benign tumors and detect tumors even at their incipient stage, and overcome blood-pool background radioactivity.
HER2-Positive Metastatic Breast Cancer: The recommended dose of lapatinib tablets is 1,250 mg given orally once daily on Days 1 to 21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1 to 14 in a repeating 21-day cycle. Lapatinib tablets should be taken at least one hour before or one hour after a meal. The dose of lapatinib tablets should be once daily (5 tablets administered all at once); dividing the daily dose is not recommended [see clinical pharmacology (12.3)]Capecitabine should be taken with food or within 30 minutes after food. If a day’s dose is missed, the patient should not double the dose the next day. Treatment should be continued until disease progression or unacceptable toxicity occurs.   


Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer: The recommended dose of lapatinib tablets is 1,500 mg given orally once daily continuously in combination with letrozole. When coadministered with lapatinib tablets, the recommended dose of letrozole is 2.5 mg once daily. Lapatinib tablets should be taken at least one hour before or one hour after a meal. The dose of lapatinib tablets should be once daily (6 tablets administered all at once); dividing the daily dose is not recommended [ see clinical pharmacology (12.3)].
A three component system and method for whitening teeth that comprises four primary active ingredients. The first component is a pre-conditioning mouth rinse comprised of a dilute aqueous solution of acetic acid and flavor enhancing additives. This component cleanses the pellicle film on the user's teeth. The second component is a bleaching gel including hydrogen peroxide. This gel also includes flavor enhancers, preservatives or surfactants necessary to formulate the gel. The preferred concentration of hydrogen peroxide is about six percent. The third component of the teeth whitening system is a polishing and pigmenting cream or paste that includes an abrasive substance and a pigmenting agent. The abrasive agent is preferably an alumina silicate and the pigmenting agent is preferably titanium dioxide particles. Flavor enhancers, a carrier, thickening agents, surfactants, preservatives and water are also added to formulate the cream or paste. Methods of use formulation of the products are included.
Fears regarding weight gain and body changes commonly plague midlife women. The aim of this paper is to discuss the impact of weight gain and body changes on midlife women across various cultural backgrounds. Midlife weight gain in women is associated with age as opposed to menopausal status. Weight gain during midlife occurs across all cultural/ethnic groups; however, African Americans and Hispanic women exhibit higher rates of weight gain than their Caucasian counterparts. Although use of menopause hormone replacement therapy does not produce a clinical difference in weight gain, exercise decreases the risk of obesity in midlife women. Cultural differences in perception of body image exist. Recognizing these differences may help clinicians better address the weight concerns of women from diverse backgrounds. A shift in focus from weight goals to cardiometabolic risk reduction may help patients feel more successful and improve health outcomes.
Disclosed are methods for treatment of a subject with left ventricle hypertrophy. Also disclosed are methods for slowing or delaying progression of left ventricle hypertrophy, as well as methods for mediating cardiac remodeling and for improving cardiac function in subjects with left ventricle hypertrophy. The methods comprise administering etelcalcetide parenterally to a subject.Disclosed are methods for treatment of a subject with left ventricle hypertrophy. Also disclosed are methods for slowing or delaying progression of left ventricle hypertrophy, as well as methods for mediating cardiac remodeling and for improving cardiac function in subjects with left ventricle hypertrophy. The methods comprise administering etelcalcetide parenterally to a subject. The present invention encompasses methods for reducing the number of target cells in a subject, such as cancer cells. The methods include administration of genetically-modified human immune cells expressing a chimeric antigen receptor or exogenous T cell receptor, which have specificity for an antigen on the target cells. Administration of the genetically- modified immune cells is preceded by the administration of a tolerance regimen, followed by administration of a lymphodepletion regimen, to improve efficacy of the therapy and persistence of the cells in vivo.
It has been demonstrated that an extensive resection (total or subtotal) significantly increases the overall survival in patients with gliomas. Yet, recent data have shown that conventional MR imaging underestimates the spatial extent of gliomas, since tumor cells were found to invade beyond MR imaging abnormalities. Thus, it is hypothesized that an extended resection with a margin beyond MR imaging-defined abnormalities-a "supratotal" resection-might improve the outcome of gliomas. However, the exact extent of supratotal resection remains unclear. Unnecessary removal of brain tissue that does not contain cancer cells can lead to neurological deficits that affect quality of life, such as impaired cognition, memory, and vision. Recently, studies from human specimens have shown that infiltrating glioma cells spread about 1cm beyond the gross and radiographic margins of the tumor. The investigators thereof propose to perform extended resection at least 1cm beyond the MRI defined margin might improve the outcome of patients with gliomas.
The investigators propose to test the hypothesis that interventions to improve insulin resistance will improve exercise capacity and World Health Organization (WHO) functional class in PAH. The investigators propose three specific aims to test this 1) A prospective 2x2 factorial design 12-week clinical trial of metformin or placebo and activity intervention or usual care to assess effect on six minute walk and WHO functional class, 2) Assessment of the interventions in Aim 1 in a subset of patients on right ventricle (RV) and peripheral muscle function and lipid content and markers of pulmonary vascular disease to define how these interventions may work in PAH and 3) Identify and prospectively test peripheral blood markers of metformin response in PAH. The broad goals of this work are to demonstrate the efficacy and mechanisms of interventions against insulin resistance in PAH and to identify which patients are most likely to benefit from these interventions, moving to precision medicine in PAH.

The investigators are planning a factorial design trial. Patients will be randomized twice. The first is metformin or placebo and is quadruple randomized. The second is mobile health (mHealth) intervention via texts or standard of care and is not blinded to the patients, but is to the investigator and thus is triple randomized.
PURPOSE: A liquid formulation containing azelastine as an active ingredient is provided to solubilize azelastine, improve dissolution rate, and enhance storage stability for a long time. CONSTITUTION: A transparent liquid composition containing azelastin contains azelastine; medium of polyethyleneglycol, propyleneglycol or triacetin; and recrystallization inhibitor. The recrystallization inhibitor is polyvinyl pyrrolidone. The polyvinylpyrrolidone is contained 0.2-10 weight parts based on azelastine. The medium is containe d50-150 weight parts based on azelastine. The composition contains dimethyl isosorbide. The soft capsule or hard capsule contains azelastin-containing transparent liquid composition.
A Dynamic Multi-Sensory Simulation System 100 for effecting behavior change includes a user interface 102 and a sensor array 106 for presenting information to a user and collecting biometrics from the user. The information and biometrics may be stored on a local computer 112 or may be transmitted to and from a remote computer 116 via a network 114. The remote computer 116 may include a remote biometrics service 116a and a dynamic experience engine 116b. The remote biometrics service 116a is operable to interpret biometic data signals representative of a users biological or physiological state. The dynamic experience engine 116b is operable to present content to a user based on a user reaching a desired biological or physiological state as determined by the remote biometics services 116a. The remote computer 116 may also comprise a first database 118a and a second database 118b.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating the patients with gastroesophageal reflux disease. That is ensured by the simultaneous complex introduction of drug preparations, namely a proton pump inhibitor, a prokinetic, an antacid and the intravenous blood laser exposure. The proton pump inhibitor is presented by Ultop 20 mg 2 times a day. The prokinetic is presented by Ganaton 250 mg 3 times a day. The antacid is Gaviscon 10 ml 3 times a day. The intravenous blood laser exposure is performed at wave length 0.405 mcm at output power in a disposable light guide end 1-1.5 mWt at pulse frequency 80 Hz in an continuous emission mode for 15 minutes. The 5-6 daily procedures of the intravenous blood laser exposure are required for mild gastroesophageal reflux disease, the prostaglandin Elevel equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less. The 9-10 daily procedures of the intravenous blood laser exposure are required for medium and severe gastroesophageal reflux disease, the prostaglandin Elevel equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less.EFFECT: method provides higher clinical effectiveness of the drug-induced therapy, earlier reduction of the symptoms, reduced length of treatment and rate of aggravations, lower drug load on the patient's body ensured by normalised lipid peroxidation, higher level of anti-inflammatory prostaglandins, normalised microcirculatory system, balanced vegetative nervous system.2 tbl, 2 ex
Resident education has traditionally devoted itself to knowledge acquisition rather than defined levels of clinical competence. Currently, inexperienced physicians are trained to perform invasive procedures such as central venous catheter (CVC) insertion according to the bedside, apprenticeship model, gaining expertise on real patients in neither a rigorous nor standardized manner. Simulators may ease trainees' transition to actual patients and avoid adverse events. This project aims to investigate the efficacy of a structured simulation training protocol in ultrasound guided CVC insertion for resident physicians. The specific aims are to compare: (1) the failure rate of CVC insertion, and (2) the number of attempts at venous cannulation, rates of technical errors and complications of CVC insertion, and time to CVC insertion on actual patients between residents who completed a structured, hands-on simulation training protocol (intervention group) and those who are trained according to the traditional, bedside apprenticeship model (control group). We hypothesize that the intervention group will obtain superior skills at CVC insertion on actual patients as compared to the control group as measured by: (1) a reduced failure rate at CVC insertion, (2) a) a reduced number of attempts at venous cannulation b) a decreased rate of technical errors and complications and c) a decreased time to insertion based on an independent rater's evaluation using a procedure checklist.
BACKGROUND: Progressive supranuclear palsy (PSP) is largely a sporadic disease with few reported familial cases. Genome-wide association studies (GWAS) in sporadic PSP in Caucasian populations have identified MAPT as the most commonly associated genetic risk locus with the strongest effect size. At present there are limited data on genetic factors associated with PSP in Asian populations.
OBJECTIVES: Our goal was to investigate the genetic factors associated with PSP in Southeast Asian PSP patients.
METHODS: Next-generation sequencing (whole-exome, whole-genome and targeted sequencing) was performed in two Asian cohorts, comprising 177 PSP patients.
RESULTS: We identified 17 pathogenic or likely pathogenic variants in 16 PSP patients (9%), eight of which were novel. The most common relevant genetic variants identified were in MAPT, GBA1, OPTN, SYNJ1, and SQSTM1. Other variants detected were in TBK1, PRNP, and ABCA7-genes that have been implicated in other neurodegenerative diseases. Eighteen patients had a positive family history, of whom two carried pathogenic MAPT variants, and one carried a likely pathogenic GBA1 variant. None of the patients had expanded repeats in C9orf72. Furthermore, we found 16 different variants of uncertain significance in 21 PSP patients in PSEN2, ABCA7, SMPD1, MAPT, ATP13A2, OPTN, SQSTM1, CYLD, and BSN.
CONCLUSIONS: The genetic findings in our PSP cohorts appear to be somewhat distinct from those in Western populations, and also suggest an overlap of the genetic architecture between PSP and other neurodegenerative diseases. Further functional studies and validation in independent Asian cohorts will be useful for improving our understanding of PSP genetics and guiding genetic screening strategies in these populations. © 2024 International Parkinson and Movement Disorder Society.
Imaging brain learning and memory circuit kinase signaling is a monumental challenge. The separation of phases-based activity reporter of kinase (SPARK) biosensors allow circuit-localized studies of multiple interactive kinases in vivo, including protein kinase A (PKA) and extracellular signal-regulated kinase (ERK) signaling. In the precisely-mapped Drosophila brain learning/memory circuit, we find PKA and ERK signaling differentially enriched in distinct Kenyon cell connectivity nodes. We discover that potentiating normal circuit activity induces circuit-localized PKA and ERK signaling, expanding kinase function within new presynaptic and postsynaptic domains. Activity-induced PKA signaling shows extensive overlap with previously selective ERK signaling nodes, while activity-induced ERK signaling arises in new connectivity nodes. We find targeted synaptic transmission blockade in Kenyon cells elevates circuit-localized ERK induction in Kenyon cells with normally high baseline ERK signaling, suggesting lateral and feedback inhibition. We discover overexpression of the pathway-linking Meng-Po (human SBK1) serine/threonine kinase to improve learning acquisition and memory consolidation results in dramatically heightened PKA and ERK signaling in separable Kenyon cell circuit connectivity nodes, revealing both synchronized and untapped signaling potential. Finally, we find that a mechanically-induced epileptic seizure model (easily shocked "bang-sensitive" mutants) has strongly elevated, circuit-localized PKA and ERK signaling. Both sexes were used in all experiments, except for the hemizygous male-only seizure model. Hyperexcitable, learning-enhanced, and epileptic seizure models have comparably elevated interactive kinase signaling, suggesting a common basis of use-dependent induction. We conclude that PKA and ERK signaling modulation is locally coordinated in use-dependent spatial circuit dynamics underlying seizure susceptibility linked to learning/memory potential.
The invention relates to the biological field of clone and expression of disintegrin site-directed mutant cDNA of gloydius ussuriensis and a protein preparation method and application thereof. A145, T146 and G148 in the disintegrin cDNA series of the gloydius ussuriensisis are mutated into C145, C146 and A148 by cDNA series of the snake venom mutant protein and then the cDNA containing 219 base pairs, corresponding protein series and the expression in escherichia coli and pichia are obtained. The preparing method is simple and easy to be operated. The invention separates and extracts general RNA from gloydius ussuriensis venom and then general cDNA is reversely transcribed through a RT-PCR method and then is mutated into polynucleotide series with a length of 219bp in a site-directed way. The invention also provides a small molecular-weight protein with a molecular weight of about 8,000 successfully expressed in escherichia coli BL21 and pichia. The protein has remarkable effect on resisting the form of blood vessels while no effect on inhibiting platelet aggregation. And the application of the invention in antitumor drugs has comparatively higher security and fewer side effects and has higher application value.
PROBLEM TO BE SOLVED: To obtain a pack material high in plugged keratinous part and aged keratin removing effect by using cylindrical titanium oxide excellent in rusting properties with a specific finely granulated metal oxide and improving adsorbability on the surface of skin. SOLUTION: This pack material is obtained by mixing cylindrical titanium oxide having 1-10μm major axis (preferably 0.01-1μm minor axis) with a finely granulated metal oxide having 5-100nm average primary particle diameter. Titanium oxide and silicic acid anhydride are preferable as the finely granulated metal oxide. The amounts of the cylindrical titanium oxide and the specific finely granulated metal oxide are about 0.05-3 pts.wt. and 0.5-20 pts.wt. based on 100 pts.wt. of the pack material, respectively. A peel off type is preferable as the form of the pack material. A polyvinyl alcohol, a polyvinyl pyrrolidone, etc., may be used as a film-forming agent in the pack material.
Sedation for Non-Invasive Procedures

The safety and efficacy of PRECEDEX have been established in pediatric patients 1 month to less than 18 years of age for sedation during non-invasive procedures. Use in this age group is based on one randomized double-blind, dose-ranging safety and efficacy trial in non-intubated pediatric patients 1 month to less than 17 years of age who required sedation prior to undergoing MRI scans [see Clinical Studies (14.2)]. An increase in frequency of bradypnea, bradycardia, hypertension and hypotension was observed in pediatric patients treated with PRECEDEX [see Adverse Reactions (6.1)]. The overall safety profile of PRECEDEX in pediatric patients was consistent with the known safety profile in adults [see Adverse Reactions (6.1)].

The safety and effectiveness of PRECEDEX have not been established in pediatric patients less than 1 month of age.

ICU Sedation

The safety and efficacy of PRECEDEX have not been established in pediatric patients for ICU sedation. One assessor-blinded trial in pediatric patients and two open label studies in neonates were conducted to assess efficacy for ICU sedation. These studies did not meet their primary efficacy endpoints and the safety data submitted were insufficient to fully characterize the safety profile of PRECEDEX for these patient populations.
PURPOSE: To obtain a weight-reducing composition, having remarkable skin beautifying and weight-reducing effects and capable of creating a tightened body line together with skin care due to treatment of the body by combining and blending caffeine with a seaweed powder and/or an its extracted essence and an essence of Ginseng Radix. CONSTITUTION: This weight-reducing composition is obtained by blending caffeine extracted from coffee beans with a powder of a seaweed such as an agar-agar or a sea tangle and/or its extracted essence and an essence of Ginseng Radix such as Panax ginseng C.A. Meyer and capable of reducing the weight due to its beautifying and weight-reducing effects by application to the skin. The amounts of the blended ingredients are preferably 0.001-5.0wt.% caffeine, 0.001-30wt.% seaweed powder and/or its extracted essence and 0.01-5.0wt.% essence of the Ginseng Radix. The composition can be utilized as a bathing agent, a massaging, a cleanser, a pack or an essence cosmetic. For example, a gel-like massaging cosmetic is applied to massage the body and a bathing agent is then placed in bath water to take a bath.  The essence cosmetic, etc., is then applied to the body as a method for reducing the weight using the composition.